Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02626234 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
A Phase 1 study of cMET-dysregulated Advanced Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 15
- Study locations
NCT02626234 is a Phase 1 study of cMET-dysregulated Advanced Solid Tumors that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 32 participants. The trial reports 15 study locations across 7 states.
The verdict
NCT02626234, a Phase 1 study of cMET-dysregulated Advanced Solid Tumors, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 15
- Study locations
Study Summary
the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
Conditions Studied
Interventions
- DRUG rosuvastatin
- DRUG INC280
- DRUG digoxin
Study Locations (15)
Other
- Novartis Investigative Site - Vienna
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Athens
- Novartis Investigative Site - Bologna
- Novartis Investigative Site - Naples
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - London
- Novartis Investigative Site - Manchester
Georgia
- Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group - Atlanta
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Antwerpen
- Novartis Investigative Site - Edegem
GR
- Novartis Investigative Site - Ioannina
MI
- Novartis Investigative Site - Milan
TO
- Novartis Investigative Site - Candiolo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-12-08 |
| Est. Completion | 2017-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02626234
The ClinicalTrials.gov registry entry for NCT02626234 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with cMET-dysregulated Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which rosuvastatin is the first listed.
NCT02626234 reports 15 study locations spanning 7 distinct geographic areas - top geographies include Other, Georgia, New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02626234 about?
NCT02626234 is a clinical study titled "A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors". the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
What is the current status of trial NCT02626234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-12-08. Estimated completion is 2017-04-28.
What conditions does trial NCT02626234 study?
This clinical trial studies the following conditions: cMET-dysregulated Advanced Solid Tumors.
What interventions are being tested in trial NCT02626234?
The interventions under investigation include: rosuvastatin (DRUG), INC280 (DRUG), digoxin (DRUG).
Who is sponsoring clinical trial NCT02626234?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02626234 being conducted?
This trial has 15 study locations across Georgia, New Hampshire, Antwerpen, GR, MI. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.